Aytu Biopharma (AYTU) Income from Continuing Operations (2010 - 2026)
Aytu Biopharma's Income from Continuing Operations came in at -$15,000 for fiscal Q4 2026 (quarter ended Jun 30, 2026), compared with -$19.88 million a year earlier.
Powered by 
Analysis
Aytu Biopharma (AYTU) Income from Continuing Operations (2010 - 2026) Analysis & Trends
For FY2026 (ended Jun 30, 2026), Aytu Biopharma's Income from Continuing Operations was -$14.25 million.
- Going back by fiscal year, Income from Continuing Operations was -$14.18 million in FY2025, -$12.52 million in FY2024, -$17.05 million in FY2023 and -$108.78 million in FY2022.
- The five-year range for quarterly Income from Continuing Operations is -$53.29 million (fiscal Q3 2022) to $3.94 million (fiscal Q3 2025).
- Business Quant data shows AYTU's Income from Continuing Operations at -$5.62 million (Q3 2026), -$10.58 million (Q2 2026) and $1.97 million (Q1 2026) in the three fiscal quarters before Q4 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Aytu Biopharma | 23.25 Mn | -92.42 Mn | 10.41 Mn | -15,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15,000.00 |
| Mar 31, 2026 | -5.62 Mn |
| Dec 31, 2025 | -10.58 Mn |
| Sep 30, 2025 | 1.97 Mn |
| Jun 30, 2025 | -19.88 Mn |
| Mar 31, 2025 | 3.94 Mn |
| Dec 31, 2024 | 665,000.00 |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | -3.38 Mn |
| Mar 31, 2024 | -2.29 Mn |
| Dec 31, 2023 | 619,000.00 |
| Sep 30, 2023 | -7.47 Mn |
| Jun 30, 2023 | -2.46 Mn |
| Mar 31, 2023 | -7.20 Mn |
| Dec 31, 2022 | -6.69 Mn |
| Sep 30, 2022 | -701,000.00 |
| Jun 30, 2022 | -16.09 Mn |
| Mar 31, 2022 | -53.29 Mn |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -27.85 Mn |
API Access
Aytu Biopharma Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=AYTU&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "AYTU", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=AYTU&period=max&api_key=YOUR_API_KEY");
const data = await res.json();